Pharma Nord Q10 used in the Q-symbio study
Pharma Nord Q10 does it again: It has occupied the headlines in health news journals around the world. Most recently, Professor Sven Aage Mortensen from Rigshospitalet in Copenhagen and his colleagues in EU and Asia presented the results of the Q-symbio study at a congress of cardiologists in Lisbon, Portugal, 23 - 28 May 2013.
420 patients from nine different countries were included in the Q-symbio study which examined the effect of Q10 supplementation on individuals believed be deficient.
Pharma Nord's Q10 dissolved in palm oil
The active treatment consisted of a soft gelatin capsule with 100 mg of Q10 three times a day for two years. The study wanted to show how well those who got Q10 performed compared to those who received the placebo.
Last year we saw another study involving healthy elderly people in the so-called KiSel-10 study. Dr. Urban Alehagen and his team used the same Pharma Nord Q10 with the selenium product SelenoPrecise – and achieved similary impressive results.
Why Q10 from Pharma Nord?
Researchers prefer Pharma Nord Q10 because it has documentation from more than 90 scientific studies which highlights its high bioavailability and safety. It is manufactured under Danish pharmaceutical control and is the official reference product for ICQA (International Coenzyme Q10 Association).
Q10 Pharma Nord is a registered medicine in several other European countries.